Want to see ARDX full AI Analyst Report?
Top Page
Ardelyx
(NASDAQ:ARDX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$5.00
▲(32.28% Upside)
Action:Reiterated
Date:08/07/26
The score is held down primarily by weak financial quality today (ongoing cash burn, negative profitability, and rising leverage) and bearish technical positioning (below key moving averages with negative MACD). Offsetting factors include strong product-driven revenue growth and improving loss trends, plus a net-positive but cautious earnings-call outlook that still points to potential profitability in 2027 despite payer-access headwinds and reduced guidance/visibility for parts of the franchise.
Positive Factors
Revenue Scale & High Gross Margins
Ardelyx has rapidly scaled product revenue to ~451M TTM while maintaining very high gross margins (~94%). This durable product economics provides strong operating leverage potential, supports reinvestment in commercialization and R&D, and improves the company’s ability to reach sustainable profitability if growth persists.
Negative Factors
Rising Leverage
Debt has more than tripled since 2023 and now materially exceeds equity, reducing financial flexibility. Elevated leverage increases interest and covenant risk, making the company more dependent on operating cash flow or external financing to fund growth until sustained profitability and cash generation are achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scale & High Gross Margins
Ardelyx has rapidly scaled product revenue to ~451M TTM while maintaining very high gross margins (~94%). This durable product economics provides strong operating leverage potential, supports reinvestment in commercialization and R&D, and improves the company’s ability to reach sustainable profitability if growth persists.
Read all positive factors
Ardelyx Key Performance Indicators (KPIs)
Any
Revenue by Segment
Separates revenue from product sales, licensing and collaboration payments, royalties, and milestones to show where the company’s money actually comes from. For Ardelyx, this reveals whether growth is driven by recurring commercial sales of its own drugs or by one‑time partner payments—steady product revenue points to sustainable commercial traction, while heavy reliance on milestones or licenses means earnings can be lumpy and more dependent on partner deals and development success.
Separates revenue from product sales, licensing and collaboration payments, royalties, and milestones to show where the company’s money actually comes from. For Ardelyx, this reveals whether growth is driven by recurring commercial sales of its own drugs or by one‑time partner payments—steady product revenue points to sustainable commercial traction, while heavy reliance on milestones or licenses means earnings can be lumpy and more dependent on partner deals and development success.
Data provided by:
The Fly
The FlyArdelyx (ARDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$941.93M
Dividend YieldN/A
Average Volume (3M)4.00M
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue Growth16.77%
EPS Growth4.11%
CountryUS
Employees489
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.23
Shares Outstanding249,187,580
10 Day Avg. Volume2,609,657
30 Day Avg. Volume4,000,766
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)8.42
Price to Sales (P/S)3.45
P/FCF Ratio-31.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.63Price Target Upside260.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$489.07M
Ardelyx Business Overview & Revenue Model
Company Description
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both d...
How the Company Makes Money
Ardelyx makes money primarily from product-based revenue tied to sales of its prescription medicines. The company’s key revenue streams include: (1) Net product sales from U.S. commercialization of IBSRELA (tenapanor) for IBS-C, generated through ...
Ardelyx Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call presents a predominantly constructive commercial and financial picture — record quarterly revenue, double-digit year-over-year growth for both marketed products, improving losses and a pathway to profitability in 2027 — but is tempered by material payer-access headwinds that slowed new patient starts for IBSRELA, a lowered near-term guidance for IBSRELA, increased operating costs to address access challenges, and pulled longer-range XPHOZAH guidance pending regulatory/market clarity. Management has taken proactive remediation steps (IPN, enlarged FRM team, expanded sales force), retains confidence in long-term potential (including $1 billion IBSRELA ambition and tenapanor IP), and maintains solid liquidity, resulting in a net-positive but cautious outlook.Positive Updates
Record Quarterly Revenue
Total product revenue of $118.0 million in Q2 2026, up 31% year-over-year — the largest quarterly revenue in company history.
Negative Updates
Access Barriers Impacting New Patient Starts
Payers implemented increased step edits and more stringent prior authorizations, which management says have slowed new patient starts for IBSRELA (not full blocks but meaningful delays), contributing to a reduction in near-term growth expectations.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Quarterly Revenue
Total product revenue of $118.0 million in Q2 2026, up 31% year-over-year — the largest quarterly revenue in company history.
Read all positive updates
Company Guidance
Ardelyx lowered 2026 IBSRELA guidance to $350–$370M (implying >30% growth at the midpoint and management expects roughly 60% of full‑year sales in the back half with Q4 the strongest quarter), reiterated XPHOZAH guidance of $110–$120M, and cut 2026 OPEX guidance to below $500M while maintaining a path to profitability in 2027. The revision is anchored in Q2 results of $118.0M total product revenue (+31% YoY) — IBSRELA $86.2M (+33% YoY) and XPHOZAH $31.9M (+27% YoY) — and operational metrics: IPN fills drive faster fulfillment and ~1 additional refill per patient annually, XPHOZAH total dispenses +33% and paid scripts +25%, a sales force expanded to 144 reps, a doubled field reimbursement team, and a GTN expectation in the low‑ to mid‑30s. Q2 operating line items included R&D $26.1M, SG&A $101.4M, net loss $16.7M (including $15.3M share‑based comp), and cash, equivalents and short‑term investments of $281.8M after a $50M draw from SLR; management also withdrew the prior $750M longer‑term XPHOZAH target pending market dynamics but kept confidence in a long‑term $1B IBSRELA opportunity.Ardelyx Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
44
Neutral
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 450.89M | 407.32M | 333.62M | 124.46M | 52.16M | 10.10M |
| Gross Profit | 423.67M | 364.72M | 283.06M | 106.66M | 48.04M | 9.10M |
| EBITDA | -23.78M | -29.17M | -16.71M | -55.35M | -60.98M | -150.85M |
| Net Income | -55.70M | -61.60M | -39.14M | -66.07M | -67.21M | -158.16M |
Balance Sheet | ||||||
| Total Assets | 575.89M | 501.60M | 435.75M | 297.58M | 190.07M | 149.91M |
| Cash, Cash Equivalents and Short-Term Investments | 281.83M | 264.69M | 250.10M | 184.30M | 123.91M | 116.69M |
| Total Debt | 256.19M | 211.59M | 153.44M | 55.98M | 36.46M | 45.50M |
| Total Liabilities | 426.88M | 334.65M | 262.46M | 130.76M | 91.74M | 67.30M |
| Stockholders Equity | 149.01M | 166.95M | 173.29M | 166.82M | 98.33M | 82.62M |
Cash Flow | ||||||
| Free Cash Flow | -17.92M | -43.98M | -45.82M | -90.06M | -70.10M | -154.42M |
| Operating Cash Flow | -17.32M | -42.48M | -44.81M | -89.72M | -70.04M | -152.55M |
| Investing Cash Flow | -34.07M | -8.96M | -18.32M | -131.25M | 18.41M | 50.95M |
| Financing Cash Flow | 58.53M | 54.51M | 106.59M | 146.29M | 75.34M | 83.00M |
Ardelyx Technical Analysis
Negative
3.78
Price Trends
4.94
Negative
5.55
Negative
5.93
Negative
Market Momentum
-0.34
Positive
29.00
Positive
15.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDX, the sentiment is Negative. The current price of 3.78 is below the 20-day moving average (MA) of 4.24, below the 50-day MA of 4.94, and below the 200-day MA of 5.93, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 29.00 is Positive, neither overbought nor oversold. The STOCH value of 15.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARDX.
Ardelyx Risk Analysis
Ardelyx disclosed 53 risk factors in its most recent earnings report. Ardelyx reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ardelyx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $2.21B | 88.42 | 6.91% | ― | 22.95% | 228.76% | |
66 Neutral | $4.80B | -23.99 | -39.01% | ― | ― | -18.88% | |
58 Neutral | $6.27B | -852.00 | -3.51% | ― | -60.77% | -27.57% | |
55 Neutral | $2.74B | -6.87 | -61.35% | ― | 23220.33% | 13.06% | |
54 Neutral | $2.60B | -11.75 | -61.24% | ― | ― | 9.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $941.93M | -16.97 | -36.00% | ― | 16.77% | 4.11% |
* Healthcare Sector Average
ARDX
Ardelyx
3.83
-2.55
-39.97%
VCEL
Vericel
42.44
6.55
18.25%
VRDN
Viridian Therapeutics
24.26
5.82
31.56%
DNTH
Dianthus Therapeutics
110.76
85.95
346.43%
PHVS
Pharvaris
37.00
14.16
62.00%
EWTX
Edgewise Therapeutics
44.38
29.73
202.94%
Ardelyx Corporate Events
Business Operations and StrategyFinancial DisclosuresLegal ProceedingsPrivate Placements and Financing
Ardelyx Updates Outlook Amid Q2 Growth and Recalibration
Neutral
Aug 6, 2026
Ardelyx reported that in the second quarter ended June 30, 2026, total product revenue rose 31% year over year to $118.1 million, driven by IBSRELA sales of $86.2 million and XPHOZAH sales of $31.9 million, while cash and investments reached $281....
Business Operations and StrategyPrivate Placements and Financing
Ardelyx Secures New $50 Million Term F Loan
Positive
Jul 2, 2026
On June 29, 2026, Ardelyx received a $50 million Term F Loan under its existing loan and security agreement with SLR Investment Corp. and other lenders, originally executed in February 2022 and amended multiple times through April 2026. The compan...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Ardelyx Shareholders Approve Equity Plan Amendment and Directors
Positive
Jun 17, 2026
On April 16, 2026, Ardelyx’s board approved a second amendment to its Amended and Restated 2014 Equity Incentive Award Plan, which was subsequently approved by stockholders at the company’s virtual annual meeting on June 16, 2026, sign...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.